GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

Eyecelerator 2020 – Virtual Conference

World Orphan Drug Congress Europe 2020 – Live Digital

4th Annual Gene Therapy for Rare Disorders Europe – Virtual

Cell & Gene Meeting on the Mesa – Virtual

Ophthalmology Futures Retina – Virtual Forum

GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology

GenSight Biologics reports new analysis demonstrating statistically significant and clinically meaningful difference between visual outcomes in LUMEVOQ®-treated patients and natural history of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)

OIS Retina Innovation Showcase